Back to Search
Start Over
ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.
- Source :
-
Urologia internationalis [Urol Int] 2017; Vol. 98 (3), pp. 282-289. Date of Electronic Publication: 2016 Dec 17. - Publication Year :
- 2017
-
Abstract
- Background/Aims/Objectives: It is difficult to identify patients with a non-muscle-invasive bladder cancer (NMIBC) at stage pT1 with concomitant carcinoma in situ (Cis) who will benefit from an early cystectomy.<br />Methods: We retrospectively analyzed clinical data and formalin-fixed paraffin-embedded tissues of patients with NMIBC. Messenger ribonucleic acid (mRNA) expression of progesterone receptor (PGR), estrogen receptor (ESR1), ERBB2, and marker of proliferation Ki-67 (MKI67) was measured by single-step reverse transcription quantitative real-time polymerase chain reaction using RNA-specific TaqMan assays. Relative gene expression was determined by the normalization of 2 reference genes (CALM2, B2M) using the 40 ΔΔCT method and relative gene expression was correlated to the histopathological stage and oncological outcome.<br />Results: Of 302 patients with pT1 NMIBC in the initial transurethral resection of the bladder, 65 had a concomitant Cis. Elevated ERBB2 expression (>40.1) significantly correlated with progress in patients with and without concomitant Cis (p = 0.020 and p = 0.049, respectively). For the subgroup of pT1 with concomitant Cis, elevated ERBB2 expression significantly discriminated between a high-risk group of 55% progression-free survival (PFS) and a low-risk group of 90% PFS after a 5-year follow-up (p = 0.020). Cox-regression analysis revealed ERBB2 expression as the only independent prognostic factor for PFS (p = 0.0037).<br />Conclusions: High mRNA expression of ERBB2 can identify patients with pT1 NMIBC with concomitant Cis, who have a high risk of progression and might benefit from an early cystectomy.<br /> (© 2016 S. Karger AG, Basel.)
- Subjects :
- Aged
Carcinoma in Situ surgery
Disease Progression
Disease-Free Survival
Estrogen Receptor alpha metabolism
Female
Humans
Kaplan-Meier Estimate
Ki-67 Antigen metabolism
Male
Middle Aged
Predictive Value of Tests
Prognosis
Proportional Hazards Models
RNA, Messenger metabolism
RNA, Neoplasm analysis
Receptor, ErbB-2 genetics
Receptors, Progesterone metabolism
Retrospective Studies
Sensitivity and Specificity
Treatment Outcome
Urinary Bladder Neoplasms surgery
Carcinoma in Situ metabolism
Cystectomy
Gene Expression Regulation, Neoplastic
Receptor, ErbB-2 metabolism
Urinary Bladder Neoplasms metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1423-0399
- Volume :
- 98
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Urologia internationalis
- Publication Type :
- Academic Journal
- Accession number :
- 27992871
- Full Text :
- https://doi.org/10.1159/000453670